✦ LIBER ✦

PCV23: A COST-BENEFIT MODEL FOR PERINDOPRIL IN SECONDARY STROKE PREVENTION

✍ Scribed by AG Hartzema; AG Winterstein; SY Kwon

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CV1 A COST-BENEFIT MODEL FOR PERINDOPRIL

✍ AG Hartzema; AG Winterstein; S Kwon 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

PCV48 Systematic Review of Cost-Effectiv

✍ B. Limone; W.L. Baker; M. Roberts; C.I. Coleman 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

A Benefit-Risk Assessment of Agents Used

✍ Dr Ronald S. MacWalter, Colin P. Shirley 📂 Article 📅 2002 🏛 Springer International Publishing AG 🌐 English ⚖ 255 KB

Cost-effectiveness of apixaban vs warfar

✍ Kamel, H.; Easton, J. D.; Johnston, S. C.; Kim, A. S. 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 578 KB

PCV53 A Cost-Effectiveness Analysis Comp

✍ M. Psenkova; S. Mackovicova; D. Tomek; J. Bielik; H. Spitzerova 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PO03-MO-08 The cost burden for secondary

✍ C.H. Kim; H.Y. Rhee 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 44 KB